AHF's Response to the FTC Lawsuit Against Pharmacy Benefit Managers
The AIDS Healthcare Foundation (AHF) strongly supports the recent actions taken by the U.S. Federal Trade Commission (FTC) against major pharmacy benefit managers (PBMs). These intermediaries have been a significant factor in driving up insulin prices, a medication that should be accessible for everyone who needs it. Insulin was never intended to be a source of profit; in fact, its original creators sold the patent for just a dollar back in 1923, believing it was wrong to profit from a life-saving drug.
The Impact of PBMs on Drug Pricing
For more than twenty years, PBMs have exploited their role within the healthcare system. The biggest players — Caremark Rx, OptumRx, and Express Scripts — are now facing legal consequences as they contend with serious allegations of anti-competitive practices related to insulin pricing. This lawsuit highlights the FTC's dedication to breaking down practices that put profit ahead of patient well-being.
A Look Back at Insulin Pricing
If we rewind to the late 1990s, the price for Humalog, a widely used form of insulin, was around $21 per vial. Fast forward to 2017, and that price had skyrocketed to an average of $274. These drastic price changes can be traced back to manipulation within the PBM sector. These organizations designed their formularies in a way that often promoted higher-priced medications, steering patients toward costlier options rather than more affordable alternatives.
AHF's Advocacy and Ongoing Commitment
AHF has been a leading voice in addressing the negative impacts of PBM practices on healthcare. The organization is acutely aware of how these middlemen exploit the healthcare system, leading to higher costs and difficulties in accessing care for vulnerable communities. The frustration many feel at the pharmacy counter is directly tied to the actions of PBMs, which prioritize profits over the health outcomes of patients.
Support from the FTC and Continuous Efforts
AHF applauds FTC Chair Khan’s ongoing efforts to uncover and penalize these damaging practices. The FTC's actions represent a crucial turning point in addressing the systemic issues that have enabled PBMs to control drug pricing while putting patient health in jeopardy.
About the AIDS Healthcare Foundation
The AIDS Healthcare Foundation is the largest provider of HIV/AIDS care globally, reaching over 2.1 million people across 47 countries. AHF is committed to delivering advanced medical care and advocacy for patients living with HIV/AIDS. Their mission goes beyond just providing health services; they also work to educate communities about healthcare access and the necessity of affordable medications.
Frequently Asked Questions
What led to the FTC's lawsuit against PBMs?
The lawsuit was initiated in response to PBM practices that inflated insulin prices and limited access to more affordable options for patients who need this critical medication.
In what ways do PBMs influence medication pricing?
PBMs tend to manipulate drug formularies in a way that favors higher-priced medications, which can result in increased costs for patients compared to what they'd typically spend on cheaper alternatives.
What role does AHF play in the issue of insulin pricing?
AHF actively advocates for patients' rights, highlighting the harmful practices of PBMs that negatively impact healthcare outcomes while also promoting policy changes aimed at fairness in drug pricing.
Why was insulin historically affordable?
Insulin was developed with the goal of making it widely accessible to those in need; its original patent was sold for just $1 to ensure it remained a public health asset rather than a profit-driven product.
What services does AHF provide for people affected by HIV/AIDS?
AHF offers comprehensive healthcare, which includes medications, support programs, and advocacy efforts aimed at enhancing the lives of those affected by HIV/AIDS around the world.
